About Alkermes
Alkermes is a publicly listed company based in Dublin (Ireland) founded in 1987. Developer of small molecule therapeutics and drug delivery technologies for multiple CNS diseases. The company has 1,800 employees. Alkermes has completed 2 acquisitions, including Avadel Pharmaceuticals and Rodin Therapeutics. Its website alkermes.com draws about 23 thousand monthly visits. Alkermes offers products and services including Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290. Its focus areas include Life Sciences, Neurology, Drugs and Diversified.
Company details
Alkermes was founded in 1987 and is based in Dublin, Ireland. Small molecule therapeutics and drug delivery technologies are developed for central nervous system (CNS) diseases. A diversified commercial product portfolio is maintained, alongside a clinical pipeline of candidates for chronic conditions including schizophrenia, depression, addiction, and multiple sclerosis. Operations focus on advancing treatments in the biopharmaceutical sector.
- Headquarters Dublin, Ireland
- Employees 1,800
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website alkermes.com
- Social LinkedIn YouTube
- Legal Name Alkermes Plc
- Annual Revenue$1.48 B (USD)-5.25as on Dec 31, 2025
- Net Profit$241.66 M (USD)-34.16as on Dec 31, 2025
- EBITDA$281.12 M (USD)-37.41as on Dec 31, 2025
- Latest Funding Round$2.31M (USD), Grant
Sep 2010
- Investors
- Employee Count1,800
- Investments & AcquisitionsAvadel Pharmaceuticals
& 1 more
Products & Services of Alkermes
Alkermes offers a comprehensive portfolio of products and services, including Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290.
Treatment for schizophrenia and bipolar disorder in adults.
Therapy for narcolepsy and idiopathic hypersomnia conditions.
Investigational treatment for central nervous system disorders.
Potential therapy for neurological and psychiatric issues.
Apps and channels of Alkermes
its YouTube channel Alkermes has 301 subscribers and 9 videos.
Videos from Alkermes
The most watched videos on Alkermes's YouTube channel, Alkermes (301 subscribers). Click a video to play it here.
More on Alkermes.
Funding Insights of Alkermes
- Total Rounds 5
- Last Round Grant — $2.31M
- First Round $50M
(Mar 1997)
- Investors Count 1
All 5 funding rounds of Alkermes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2010 | $2.31M | Grant | – | – | |
| Feb 2005 | $170M | Debt – Venture | – | – | – |
| Aug 2003 | $100M | Post-IPO | – | – | – |
| Jan 2003 | $30M | Post-IPO | – | – | – |
| Mar 1997 | $50M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Alkermes
Alkermes has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Alkermes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alkermes
517 people are tracked at Alkermes (258 in leadership, 10 in board & advisors, 249 in team); the tracked headcount is 1,800.
| Name | Role | Group |
|---|---|---|
Blair C. Jackson | EVP & COO | Leadership |
Craig Hopkinson | Chief Medical Officer & SVP, Medicines Development & Medical Affairs | Leadership |
Richard F. Pops | CEO & Chairman | Leadership |
David J. Gaffin | SVP, Chief Legal Officer, Chief Compliance Officer & Secretary Alkermes plc | Leadership |
Jeremy Edgerton | Director, Translational Medicine | Leadership |
Marcelo Loureiro | Head Of Global Procurement & Trade Compliance | Leadership |
Pete Mello | Executive Director, Talent Aquisition | Leadership |
Thomas Harvey | Chief Information Officer & SVP, IT | Leadership |
Ken Adams | Vice President, Head Of Clinical Operations | Leadership |
Emily Check-Davis | Associate Director, HCP Marketing - Lybalvi (olanzapine And Samidorphan) | Leadership |
Kristen Yafrate | Director, Thought Leader Engagement Marketing | Leadership |
Jed Rosenbaum | Vice President, Marketing | Leadership |
Janine Shea | Vice President Market Access Strategy And Marketing | Leadership |
Saru Wade | Vice President, Brand Lead - Lybalvi (olanzapine And Samidorphan) | Leadership |
Lisa Frankina | Director Of Digital Marketing | Leadership |
Lucas W. | Senior Medical Director: Pipeline / Addiction | Leadership |
Jenni Moore | Associate Director Sourcing | Leadership |
Erik Weeden | Director, Field Incentive Compensation | Leadership |
W. George Lai | Head Of DMPK And Bioanalysis | Leadership |
Tom Ryan | Executive Director Hr, HRBP And Talent Development | Leadership |
497 more people are available in the full profile.
Complete people profiles for Alkermes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alkermes
Alkermes is a publicly listed company on the NASDAQ with ticker symbol ALKS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jul 1991
- Listed onNASDAQ: ALKS
- Listed entityAlkermes plc
- Exchange sectorHealth technology
- ISINIE00B56GVS15
- Share price$39.73 (-1.32% on the day) · 2026-10-13
- Market capitalisation$6.67B
- Price to earnings103.2
- EPS (diluted, trailing year)$0.39
- Volume (last session)1,068,285
Financials of Alkermes
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.48B | $241.7M | $281.1M |
| 2024 | $1.56B | $367.1M | $449.2M |
| 2023 | $1.66B | $355.8M | $489.1M |
| 2022 | $1.11B | -$158.3M | $71.8M |
| 2021 | $1.17B | -$48.2M | $49.4M |
Detailed financial statements for Alkermes
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alkermes
Alkermes has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Avadel Pharmaceuticals and Rodin Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proprietary drug delivery technologies and narcolepsy treatments are developed. | avadel.com | Dublin, Ireland | 1990 | Oct 2025 | $2.1B | |
Epigenetic modulators are developed for CNS disorder treatments. | rodintherapeutics.com | Cambridge, United States | 2013 | Nov 2019 | $100M |
Complete acquisition details for Alkermes
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alkermes
6 dated milestones of Alkermes across 38 years, from founding to its latest funding, stage changes and deals.
- Founded Alkermes is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $50.0M.
- Funding Latest funding round, Grant, of $2.3M.
- Acquisition Acquires Rodin Therapeutics.
- Acquisition Acquires Avadel Pharmaceuticals.
Web traffic of Alkermes
The website of Alkermes (alkermes.com) receives about 22.7K visits a month and ranks #1,117,011 among all websites worldwide, #1,385 in Biotechnology and Pharmaceuticals.
- Monthly visits22.7K
▲ 5.6% vs previous month
- Unique visitors10.1K
per month
- Global rank#1,117,011
among all websites
- Category rank#1,385
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.5
- Average visit22 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Alkermes. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| merck.com | 100% | 656.8K | #78,842 | View details | |
ppdi.com | ppdi.com | 87% | #404,899 | – | |
| keryx.com | 87% | View details | |||
| medivation.com | 87% | View details | |||
| perrigo.com | 87% | 61.1K | #524,398 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 33 similar websites and full traffic analytics for Alkermes
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 33 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alkermes
Complete news archive for Alkermes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alkermes
Alkermes was founded in 1987 and raised its 1st funding round 10 years after it was founded.
Alkermes is headquartered in Dublin, Ireland.
Alkermes has 1,800 employees.
Annual revenue of Alkermes is $1.48B as on Dec 31, 2025.
Alkermes was founded in 1987 and is based in Dublin, Ireland. Small molecule therapeutics and drug delivery technologies are developed for central nervous system (CNS) diseases. A diversified commercial product portfolio is maintained, alongside a clinical pipeline of candidates for chronic conditions including schizophrenia, depression, addiction, and multiple sclerosis. Operations focus on advancing treatments in the biopharmaceutical sector.
Alkermes offers Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290.
Yes, Alkermes is publicly traded on NASDAQ under the ticker symbol ALKS.
Alkermes has made 2 acquisitions, including Avadel Pharmaceuticals, and Rodin Therapeutics.
Alkermes has 1 investor. Key investors include HHS.